Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release

ASKA Pharmaceutical Holdings Co., Ltd.

Assignment of Responsibilities to Board Members and Corporate Officers

TOKYO, June 24, 2026 - ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886, Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi) transitioned to a Company with an Audit and Supervisory Committee upon approval at the 5th Ordinary General Meeting of Shareholders held on June 24, 2026. At the same meeting and the subsequent meeting of the Board of Directors, the Company resolved the assignment of responsibilities to its Board Members (including Board Members who are Audit and Supervisory Committee members) and Corporate Officers as set forth below.

1. Board Member

Takashi Yamaguchi	Member of the Board of Directors, Representative Director, Chairman of the Board (Member of the Board of Directors, Representative Director, Chairman of the Board of ASKA Pharmaceutical Co., Ltd.)
Sohta Yamaguchi	President, Member of the Board of Directors, Representative Director (President, Member of the Board of Directors, Representative Director of ASKA Pharmaceutical Co., Ltd.)
Atsushi Maruo	Senior Managing Member of the Board of Directors, Representative Director, In Charge of Sustainability (Member of the Board of Directors, Vice Chairman of the Board of ASKA Pharmaceutical Co., Ltd.)
Maiko Mori	Member of the Board of Directors, Executive Corporate Officer (Member of the Board of Directors, Executive Corporate Officer, Quality & Safety Assurance Division Director of ASKA Pharmaceutical Co., Ltd.)
Fumiyoshi Yamaguchi	Member of the Board of Directors, Executive Corporate Officer (President, Member of the Board of Directors, Representative Director of ASKA Animal Health Co., Ltd.)
Minoru Awabayashi	Member of the Board of Directors, Outside Director
Yasuji Enokido	Member of the Board of Directors, Outside Director
Kanae Karita	Member of the Board of Directors, Outside Director
Kiyoko Kato	Member of the Board of Directors, Outside Director
James C. Feliciano	Member of the Board of Directors, Outside Director

2. Board Members who are Audit & Supervisory Committee Members

Kunihiro Gunji	Member of the Board of Directors, Audit and Supervisory Committee Member (Audit & Supervisory Board Member of ASKA Pharmaceutical Co., Ltd., Audit & Supervisory Board Member of ASKA Pharma Medical Co., Ltd.)
Takao Kimura	Member of the Board of Directors, Outside Director, Audit and Supervisory Committee Member
Koki Yamashita	Member of the Board of Directors, Outside Director, Audit and Supervisory Committee Member

Note: Kazuhiro Chiku, Audit & Supervisory Board Member, retired from his position effective June 24, 2026.

3. Corporate Officers

Kiyohiko Tamura	Executive Corporate Officer Group Business Management Division Director In Charge of DX Promotion (Executive Corporate Officer, Administrative Division Director of ASKA Pharmaceutical Co., Ltd.)
Tomohito Nagao	Corporate Officer In Charge of Audit and Legal Affairs & Regulatory Compliance (Corporate Officer, Director, Promotion Compliance Unit of ASKA Pharmaceutical Co., Ltd.)
Hidenori Hori	Corporate Officer (President, Member of the Board of Directors, Representative Director of ASKA Pharma Medical Co., Ltd.)

Note: Junichi Saito, Corporate Officer, retired from his position effective June 24, 2026.

Media Contacts
ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp